Additional Information
Book Details
Abstract
Multiple Sclerosis 3 emphasizes the latest in the pharmacologic treatment of this incurable inflammatory demyelinating disorder. Primary editors Claudia Lucchinetti, MD, and Reinhard Hohlfeld, MD, with the aid of all new contributors, present a complete and current reference on multiple sclerosis that includes discussions of such hot topics as Biomarkers, Genomics, and Surrogate Outcomes in MS; Pediatric MS; Transverse Myelitis; Attack Therapies in MS; Current Disease-Modifying Therapeutic Strategies in MS; Management of Aggressive MS; Symptomatic Therapies in MS; Complementary and Alternative Medical Therapies; and Strategies to Promote Neuroprotection and Repair. Distinguish between MS and other similar demyelinating disorders and know the best and most aggressive methods of treatment. This title in the Blue Books of Neurology series is exactly what you need to treat the disease and its relapses.
- Covers the latest clinical advances and relevant discussions—Biomarkers, Genomics, and Surrogate Outcomes in MS; Pediatric MS; Transverse Myelitis; Attack Therapies in MS; Current Disease-Modifying Therapeutic Strategies in MS; Management of Aggressive MS; Symptomatic Therapies in MS; Complementary and Alternative Medical Therapies; and Strategies to Promote Neuroprotection and Repair—to bring you up to date and keep your practice state-of-the-art.
- Features a greater emphasis on practical management to help you determine the type of multiple sclerosis and the best course of therapy.
- Focuses on pharmaceutical therapies so you know the best and most aggressive methods and which drugs to use for treatment.
- Includes extensive information on differential diagnosis so that you can clearly distinguish between multiple sclerosis and other similar demyelinating disorders.
- Presents expert new editors and experienced contributing authors for the most current and relevant practice information.
- Emphasizes the pharmacologic management of patients with multiple sclerosis to address treating the actual disease and its relapses as well as treating the symptoms.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover\r | Cover | ||
| MULTIPLE SCLEROSIS 3\r | iii | ||
| Copyright\r | iv | ||
| BLUE BOOKS OF NEUROLOGY\r | v | ||
| CONTENTS\r | ix | ||
| CONTRIBUTING AUTHORS\r | xi | ||
| SERIES PREFACE\r | xix | ||
| PREFACE | xxi | ||
| Chapter 1\rClinical Features and Natural History of Multiple Sclerosis:The Nature of the Beast | 1 | ||
| Disability Progression: \rWhat Happens to Patients over Time? | 2 | ||
| What Affects Long-Term Disability Outcome? | 4 | ||
| Benign Multiple Sclerosis | 13 | ||
| References | 17 | ||
| Chapter 2\rDifferential Diagnosis and Diagnostic Criteria for Multiple Sclerosis: Application and Pitfalls | 19 | ||
| Multiple Sclerosis Diagnostic Criteria | 20 | ||
| Idiopathic Inflammatory Demyelinating \rDiseases | 27 | ||
| Differential Diagnosis | 31 | ||
| Conclusion | 39 | ||
| Chapter 3\rUncovering the Genetic Architectureof Multiple Sclerosis | 43 | ||
| The MHC and Multiple \rSclerosis Susceptibility | 44 | ||
| A Meta-analysis of MHC Studies in Multiple Sclerosis | 46 | ||
| Whole Genome Scan Methodology and Its Application in Multiple Sclerosis | 47 | ||
| Genome Scan Results: What Do They Mean? | 49 | ||
| Integrating Disease Risk | 51 | ||
| Susceptibility to Autoimmunity | 51 | ||
| The Impact and Role of Genetic Analysis in Multiple Sclerosis Research and Care | 53 | ||
| References | 54 | ||
| Chapter 4\rEpidemiology of Multiple Sclerosis:Environmental Factors | 57 | ||
| Epidemiology in Perspective | 57 | ||
| Descriptive Epidemiology of Multiple Sclerosis | 58 | ||
| Infection and Multiple Sclerosis | 62 | ||
| Sunlight Exposure and Vitamin D | 67 | ||
| Cigarette Smoking | 71 | ||
| Other Possible Risk Factors | 72 | ||
| References | 75 | ||
| Chapter 5\rAdvances in Multiple Sclerosis Imaging | 83 | ||
| Physics of Magnetic \rResonance Imaging | 84 | ||
| High-Field-Strength Magnetic Resonance Imaging | 85 | ||
| Conventional Magnetic Resonance Imaging Techniques | 85 | ||
| The role of Magnetic Resonance Imaging in the Diagnostic Criteria of Multiple Sclerosis | 94 | ||
| The Role of Magnetic Resonance Imaging in Treatment Decisions | 93 | ||
| Advanced Magnetic Resonance Imaging Techniques | 100 | ||
| The Role of MRI in the Diagnosis of Tumefactive Demyelinating Lesions | 106 | ||
| Magnetic Resonance Imaging of Neuromyelitis Optica | 107 | ||
| Acute Disseminated Encephalomyelitis | 109 | ||
| Non–MRI-Based Advanced Imaging Techniques: Optical Coherence Tomography | 111 | ||
| Conclusions | 112 | ||
| References | 113 | ||
| Chapter 6\rBiomarkers in Multiple Sclerosis | 120 | ||
| Definitions of Biomarkers | 121 | ||
| Biomarkers Related to Diagnosis and Prognosis | 122 | ||
| Biomarkers for Treatment Responses | 132 | ||
| Novel Technologies for the Identification of Novel Biomarkers | 134 | ||
| Concluding Remarks | 139 | ||
| References | 139 | ||
| Chapter 7\rCognitive and Psychiatric Disorders in Multiple Sclerosis | 147 | ||
| Cognitive Dysfunction | 147 | ||
| Assessment\r | 152 | ||
| Psychiatric Disorders\r | 154 | ||
| References\r | 156 | ||
| Chapter 8\rGender Differences in Multiple Sclerosis | 159 | ||
| Gender Differences in Multiple Sclerosis | 160 | ||
| Gender Differences in the Murine Model of Multiple Sclerosis | 161 | ||
| The Effects of Pregnancy in Clinical Multiple Sclerosis | 163 | ||
| The Effects of Ovarian Hormones in Multiple Sclerosis | 168 | ||
| The Effects of Testicular Hormones in Multiple Sclerosis | 172 | ||
| Effect of Endogenous Androgens in the Mouse Model of Multiple Sclerosis | 172 | ||
| The Effects of Sex Chromosomes in Multiple Sclerosis | 175 | ||
| Conclusions | 178 | ||
| References | 179 | ||
| Chapter 9\rHistorical Background | 185 | ||
| Historical Background | 185 | ||
| Epidemiology | 186 | ||
| Clinical Characteristics | 187 | ||
| Clinical Course of Multiple Sclerosis in Children | 191 | ||
| Investigations and Differential Diagnosis | 196 | ||
| Neuroimaging Features of Multiple Sclerosis in Children | 196 | ||
| Conclusion | 200 | ||
| References | 201 | ||
| Chapter 10\rClinically Isolated Syndromes | 206 | ||
| Natural History of CIS | 207 | ||
| Clinical, Imaging, and Laboratory Predictors of Outcomein CIS | 209 | ||
| Medical Management of CIS | 211 | ||
| References | 215 | ||
| Chapter 11\rAcute Disseminated Encephalomyelitis | 219 | ||
| Definitions of Acute Disseminated Encephalomyelitis | 220 | ||
| Clinical Characteristics of ADEM | 221 | ||
| Practical Recommendations for Clinicians | 232 | ||
| References | 234 | ||
| Chapter 12\rTransverse Myelitis: Pathogenesis, Diagnosis, and Management | 237 | ||
| Clinical Features\r | 238 | ||
| Natural History\r | 238 | ||
| Immunopathogenesis\r | 239 | ||
| Diagnosis and Classification of Transverse Myelitis | 241 | ||
| Management and Treatment of Transverse Myelitis | 246 | ||
| The Future\r | 254 | ||
| References\r | 254 | ||
| Chapter 13\rNeuromyelitis Optica | 258 | ||
| History | 259 | ||
| Epidemiology | 260 | ||
| Clinical Presentation and Natural History | 261 | ||
| The NMO-IgG Biomarker | 262 | ||
| Treatment | 272 | ||
| Conclusion | 273 | ||
| References | 274 | ||
| Chapter 14\rAttack Therapies in Multiple Sclerosis | 276 | ||
| Glucocorticosteroid Therapy \rfor Acute Multiple Sclerosis Relapses | 277 | ||
| Plasma Exchange Therapy for Acute Deterioration in Relapsing and Secondary Progressive Multiple Sclerosis | 279 | ||
| Conclusion | 281 | ||
| References | 282 | ||
| Chapter 15\rCurrent Disease-ModifyingTherapeuticStrategiesin MultipleSclerosis | 284 | ||
| General Therapeutic \rStrategies for Multiple Sclerosis | 284 | ||
| Overview of Currently Approved Therapies | 286 | ||
| Treatment Strategies: Relapsing-Remitting Disease | 290 | ||
| Strategies for Secondary Progressive Multiple Sclerosis | 297 | ||
| Strategies for Primary Progressive Multiple Sclerosis | 298 | ||
| Strategies for Very Stable Patients: Stopping Therapy | 299 | ||
| Conclusions | 299 | ||
| Chapter 16\rManagement of Aggressive MultipleSclerosis: Optionsand Challenges | 304 | ||
| Diagnosis of Menacing Multiple Sclerosis | 304 | ||
| Use of Therapeutic Plasma Exchange, Cyclophosphamide, and Mitoxantrone in Catastrophic Multiple Sclerosis | 306 | ||
| Use of Mitoxantrone, Alemtuzumab,and Cyclophosphamide in Aggressive Multiple Sclerosis | 310 | ||
| Conclusion | 313 | ||
| References | 314 | ||
| Chapter 17\rSymptomatic Therapy in Multiple Sclerosis | 316 | ||
| Neuro-ophthalmology | 317 | ||
| Vestibular Dysfunction | 321 | ||
| Neurogenic Bowel | 322 | ||
| Neurogenic Bladder | 326 | ||
| Sexual Dysfunction | 329 | ||
| Fatigue | 333 | ||
| Heat Intolerance | 336 | ||
| Pain | 340 | ||
| Spasticity | 341 | ||
| Conclusion | 349 | ||
| References | 349 | ||
| Chapter 18\rUnconventional Medicineand Multiple Sclerosis: The Role of Conventional HealthProviders | 355 | ||
| rDefinitions | 356 | ||
| Multiple Sclerosis: Conventional and Unconventional Medicine | 356 | ||
| Disease-Modifying Effect | 358 | ||
| Disease-Modifying and Symptomatic Effect | 362 | ||
| Symptomatic Effect | 366 | ||
| Conclusion | 368 | ||
| References | 368 | ||
| Chapter 19\rIs Multiple Sclerosisa Neurodegenerative Disorder? | 371 | ||
| Neurologic Disability in Relapsing-Remitting Multiple Sclerosis | 372 | ||
| Neurologic Disability in Secondary Progressive Multiple Sclerosis | 375 | ||
| Neuronal Compensation | 378 | ||
| Cortical Demyelination | 380 | ||
| Future Challenges | 383 | ||
| References | 384 | ||
| Chapter 20\rLessons from the Pastand Future Approachesfor Immunologic Therapies in Multiple Sclerosis | 388 | ||
| Lessons from the Past | 389 | ||
| Future Therapies | 407 | ||
| Conclusion | 417 | ||
| References | 419 | ||
| Chapter 21\rStrategies to Promote Neuroprotectionand Repairin Multiple Sclerosis | 427 | ||
| The Immunologic Basis of \rCentral Nervous System Injury in Multiple Sclerosis and Its Relevance to Repair | 428 | ||
| Animal Models of Myelin Diseases | 429 | ||
| Does Immunomodulation Protect the Multiple Sclerosis Brain from Injury? | 430 | ||
| Novel Approaches for Neuroprotection in Multiple Sclerosis | 431 | ||
| Enhancing Repair Processes in Multiple Sclerosis | 433 | ||
| Is Stem Cell Therapy a Rational Approach for Multiple Sclerosis? | 436 | ||
| Conclusions | 441 | ||
| References | 442 | ||
| INDEX | 451 |